(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/129410 A1

(51) International Patent Classification:
A61K 31/496 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:
PCT/EP2021/086308

(22) International Filing Date:
16 December 2021 (16.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20306589.1 16 December 2020 (16.12.2020) EP

(71) Applicant: **AB SCIENCE** [FR/FR]; 3 avenue George V, 75008 Paris (FR).

(72) Inventors: **MOUSSY, Alain**; 22 bis passage Dauphine, 75006 Paris (FR). **MANSFIELD, Colin**; 3 Allée Abbé Dorenlot, 14280 Saint-Contest (FR).

(74) Agent: **ICOSA**; 83 avenue Denfert-Rochereau, 75014 Paris (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

WO 2022/129410 A1

(54) Title: MASITINIB FOR THE TREATMENT OF ALZHEIMER'S DISEASE

(57) Abstract: The present invention relates to a 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of less severe and/or early-stage Alzheimer's disease in a patient in need thereof. In particular, the present invention relates to masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of Alzheimer's disease in a patient having a baseline ADCS-ADL (Alzheimer's Disease Cooperative Study–Activities of Daily Living) score equal to or greater, preferably greater than 32, having a baseline MMSE (Mini-Mental State Examination) score equal to or greater than 13, having a time from diagnosis to treatment initiation with masitinib, or a pharmaceutically acceptable salt or solvate thereof, equal to or less than 5 years, and/or having a baseline ADAS-Cog (Alzheimer's Disease Assessment Scale–Cognitive Subscale) score equal to or lower than 40.